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Gliomas form a heterogeneous group of tumours of the central nervous
system. Most gliomas, the so-called ‘diffuse gliomas’, are characterized
by diffuse infiltrative growth in the neuropil. Based on histopathological
analysis, diffuse gliomas are subdivided in astrocytic, oligodendroglial,
and oligoastrocytic tumours and graded as WHO grade II (low grade),
WHO grade III (anaplastic), or WHO grade IV (glioblastoma). Accurate
distinction between the different diffuse glioma types and malignancy
grades has significant prognostic and therapeutic implications. This
review describes essential aspects of the microscopic diagnosis of diffuse
gliomas. Because of problems with tissue sampling and imprecise criteria
for typing and grading, unequivocal histopathological classification of
diffuse gliomas can be challenging. The addition of molecular parameters
contributes to a more objective pathological diagnosis of diffuse gliomas.
A multidisciplinary approach is mandatory for achieving an optimal diag-
nosis for patients with these tumours.
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DIAGNOSTIC HISTOPATHOLOGY 17:11 486IntroductionThe histogenesis and biological behaviour of primary tumours of
the central nervous system (CNS) and its coverings is very
diverse. Over half of such tumours encountered in the general
population are benign, the major categories being meningiomas,
schwannomas and pituitary adenomas (Figure 1).1 The most
frequent primary malignant tumour of the CNS is glioma.
Gliomas are considered to originate from glial (progenitor) cells
or stem cells that develop glial characteristics. The group of
gliomas encompasses many different histological types and
malignancy grades. The most malignant tumour in this group,
i.e. glioblastoma (WHO grade IV), is by far the most common
glioma. Most gliomas are characterized by diffuse infiltrative
growth of tumour cells in the preexistent parenchyma of the CNS
and can be typed based on their histopathological features as
astrocytic, oligodendroglial, or oligoastrocytic tumours. Addi-
tionally, a malignancy grade is attributed to these gliomas based
on the presence of esp. the following features: nuclear atypia,
mitotic activity, florid microvascular proliferation, and necrosis.
The histopathological diagnosis is the gold standard for the
classification of gliomas. An adequate microscopic diagnosis
carries important prognostic information and forms the basis for
further patient management. Even after the current standard of
care (surgery, radiotherapy and chemotherapy) most glioblas-
toma patients die within 1e2 years after diagnosis. In contrast,
patients with a WHO grade II glioma may survive for over 10
years, but sooner or later such tumours generally progress to
a high-grade malignant lesion. Distant metastases of diffuse
gliomas are very rare. Still, because of their locally aggressive
behaviour and the fact that they cannot be cured by current
therapies, diffuse gliomas are considered as one of the most
devastating cancers.
Unequivocal histopathological classification of diffuse gliomas
can be challenging because of e.g. problems with tissue sampling
and the fact that the biological diversity in the spectrum of these
tumours is difficult to capture in precise histopathological
criteria. As it is impossible to cover all such aspects in one
review, we will stress the essentials of the microscopic diagnosis
as proposed by the most recent WHO edition (2007) on tumours
of the CNS.2 For detailed information on the diagnosis of
diffuse gliomas, the value of immunohistochemistry, or the intra-
operative diagnosis by frozen sections and/or smears, the reader
is referred to other recent review articles and textbooks.3e7
Molecular analysis aids in more robust classification of diffuse
gliomas into clinically meaningful subgroups. We briefly
summarize the state of the art in this field, this summary is based
on the recent, detailed review of Riemenschneider et al. on
molecular diagnostics in gliomas.8 Finally, we stress the impor-
tance of a multidisciplinary approach for obtaining an optimal
diagnosis in patients who suffer from diffuse gliomas.
MorphologyMicroscopic recognition of diffuse gliomasMacroscopic evaluation of biopsies or resection specimens is
generally of little help in reaching a diagnosis of diffuse glioma.
In larger specimens a gradual transition of normal appearing grey
or white matter into a lesion with greyish discolouration and
blurring of the preexistent anatomical structures may be seen, 2011 Elsevier Ltd. All rights reserved.
Figure 1 Relative frequency of primary brain tumours; information based on 158,088 patient diagnoses in 2004e2006 (CBTRUS Statistical Report 2010;
see CBTRUS.org).
MINI-SYMPOSIUM: NEURO-ONCOLOGYcompatible with the presence of a diffuse glioma. In this context
necrosis indicates high-grade malignancy, particularly in patients
who did not previously receive radio- or chemotherapy. Exten-
sive calcification is more often found in oligodendroglial than in
astrocytic tumours. However, microscopic analysis is required
for a specific pathological diagnosis of diffuse glioma. Following
the criteria of the WHO classification of tumours of the central
nervous system,2 diffuse gliomas are microscopically typed as
astrocytic, oligodendroglial or oligoastrocytic gliomas and graded
as WHO grade II, III or IV.
It is important to exclude other diagnoses before reaching the
diagnosis of diffuse glioma. To achieve this, the pathologist
should follow a decision tree (Figure 2). Especially in biopsy
specimens that are small or suboptimally preserved theFigure 2 Decision tree for step-by-step exclusion of differential diagnostic
options in the microscopic diagnosis of diffuse gliomas.
DIAGNOSTIC HISTOPATHOLOGY 17:11 487distinction between normal and abnormal tissue can already be
problematic. Various non-neoplastic changes such as reactive
astrocytosis, inflammatory lesions (e.g. multiple sclerosis), and
infarcts may be difficult to distinguish from diffuse glioma.
Occasionally, high-grade diffuse gliomas may show extensive
areas with epithelial or sarcomatoid parts suggestive of meta-
static carcinoma or sarcoma. Immunohistochemistry for glial
fibrillary acidic protein (GFAP) and a spectrum of other markers
(CD68, keratins, EMA, S100, neuronal markers) are generally
helpful in this respect as well as in the differential diagnosis of
diffuse gliomas with other, non-glial, primary CNS tumours such
as schwannoma, meningioma, neurocytoma, and primitive
neuroectodermal tumour (PNET).
Within the group of glial neoplasms, diffuse gliomas should
be distinguished from other gliomas. The latter include the
so-called ‘circumscribed’ gliomas (e.g. pilocytic astrocytomas,
pleiomorphic xanthoastrocytomas), ependymal tumours and
neoplasms showing a combination of glial and neuronal differ-
entiation (gangliogliomas, glioneuronal tumours, PNETs). The
presence of Rosenthal fibres and eosinophilic granular bodies in
a glial tumour contributes to the diagnosis of circumscribed
glioma or ganglion cell tumour. Additional features that are
helpful to separate ‘other’ gliomas from diffuse gliomas are
biphasic growth pattern (pilocytic astrocytoma), the presence of
abnormal (clusters of) ganglion cells (ganglioglioma), the
formation of true rosettes or perivascular pseudorosettes (epen-
dymal tumours), and immunohistochemical staining for e.g.
neuronal markers such as synaptophysin and Neu-N (ganglio-
glioma) or for EMA (ependymal tumours).
Recognition of extensive, diffuse infiltrative growth in preex-
istent brain tissue is of great help in the diagnosis of diffuse
glioma. Histopathologically, the tumour cells tend to invade
individually or in small groups in the neuropil, i.e. the network of
neuronal and glial cell processes in grey and white matter. Only
few neoplasms other than diffuse gliomas (lymphomas, occa-
sionally metastases of small cell carcinoma) display such growth 2011 Elsevier Ltd. All rights reserved.
MINI-SYMPOSIUM: NEURO-ONCOLOGYin the CNS. Furthermore, the arrangement of diffuse infiltrative
glioma cells along pre-existing tissue elements is very helpful in
recognizing a tumour as diffuse glioma. Hans-Joachim Scherer,
a pioneer in the study of glioma growth patterns, designated such
arrangements as “secondary structures”. Examples of secondary
structures are perineuronal growth (perineuronal satellitosis),
surface/subpial growth, perivascular growth, and intrafascicular
growth (Figure 3). Diffuse gliomas tend to invade over large
distances along myelinated fibre tracts and in many patients the
tumour cells cross the corpus callosum via such intrafascicular
growth.9
Of note, the circumscribed gliomas may show some infiltra-
tion in the neuropil as well, but by far not as extensive as
encountered in diffuse gliomas and typically without the forma-
tion of secondary structures of Scherer. Vice versa, it may be
impossible to appreciate diffuse infiltrative growth in highly
cellular regions of diffuse gliomas, e.g. in the core of high-grade
malignant lesions. Features of high-grade malignancy such as
brisk mitotic activity and necrosis strongly favour a diagnosis of
diffuse rather than circumscribed glioma because the latter
infrequently shows malignant progression.Typing of diffuse gliomasBased on the resemblance of the tumour cells with non-neoplastic
glial cells (astrocytes, oligodendroglial cells), most diffuse gliomas
can be typed as astrocytic, oligodendroglial, or mixed oligoas-
trocytic tumours. Normal astrocytes are stellate cells with an oval-
to-elongate, somewhat vesicular nucleus, little eosinophilic
cytoplasm and delicate eosinophilic cell processes. The phenotype
of these cells and their processes is hard to identify in the fine
fibrillar neuropil network without immunohistochemical (GFAP)
staining. Reactive astrocytes often show marked increase in
cytoplasm with some enlargement of the nucleus and more stoutFigure 3 Diffuse infiltrative glioma growth. Schematic representation (a) and m
preexistent brain parenchyma with secondary structures of Scherer: accumula
head), around blood vessels (arrow), under the pia (asterisk), and tumour ce
b: Haematoxylin-and-eosin staining, orig. magn. 200.
DIAGNOSTIC HISTOPATHOLOGY 17:11 488cellular processes, or may undergo gemistocytic change with
a plump, rounded or angular, eosinophilic cell body and an
eccentric nucleus. Astrocytic tumour cells may show a mixture of
these phenotypes with variable nuclear atypia and mitotic activity.
Because of the diffuse infiltration, various reactive glial cells are
intermixed with the tumour cells and the neuropil may be repre-
sented by relatively normal white or grey matter or may have
undergone microcystic or fibrillar change. Several phenotypical
variants of diffuse low-grade astrocytoma are described in the
WHO classification: fibrillary astrocytoma, the most common
phenotype composed of tumour cells with clear fibrillary cell
processes; protoplasmic astrocytoma which consists of tumour
cells with small cell bodies with few, flaccid processes; and
gemistocytic astrocytoma, consisting of at least 20% of cells with
the aforementioned plump phenotype. Gemistocytic astrocytomas
often harbour dispersed perivascular lymphocytic infiltrates and
tend to show more rapid malignant progression than other WHO
grade II astrocytomas.
Normal oligodendroglial cells are characterized by a round
nucleus with a relatively dense and delicate chromatin pattern
and a perinuclear halo and lack of staining for GFAP. Typical
oligodendroglial tumour cells also have a round rather than
oblong nucleus and with a perinuclear halo. Oligodendroglial
tumours are often highly cellular lesions with compact fields of
relatively small and round cells and less cellular areas in which
the diffuse infiltrative nature is more easily appreciated, e.g. in
the form of perineuronal satellitosis. Additional features indica-
tive of oligodendroglial rather than astrocytic differentiation are
the presence of a branching network of delicate capillaries
(‘chickenwire pattern’) and extensive calcification in the tumour.
Some oligodendroglial tumours show scattered cells with marked
polymorphism (‘polymorphic oligodendroglioma’) or cells
arranged in a rhythmic/spongioblastic fashion.icroscopic example (b) showing diffuse infiltration of glioma cells in the
tion of tumour cells around neurons (perineuronal satellitosis, arrow
lls migrating along white matter tracts (intrafascicular growth; þ in a).
 2011 Elsevier Ltd. All rights reserved.
Figure 4 Microscopic criteria used for grading of diffuse gliomas.
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features is acceptable for the diagnosis of pure oligoden-
droglioma. Esp. in the peripheral, diffuse infiltrative part of
oligodendroglial tumours the neoplastic cells may acquire
a non-descript or even more astrocytic phenotype. Furthermore,
in pure oligodendroglial tumours part of the tumour cells may
show a gliofibrillary or minigemistocytic phenotype with strong
GFAP staining of the cytoplasm. It is important to realize that the
presence of perinuclear halos in oligodendroglial tumours is in
fact the result of delayed fixation and can thus be absent in
specimens that are more promptly fixed or used for frozen
section diagnosis. One should thus exert great caution
when asked to precisely type (and grade) diffuse gliomas
intra-operatively using frozen sections or smears.7,10,11
As indicated by their name, the key criterion for the diagnosis
of mixed oligoastrocytomas is the presence of neoplastic glial
cells with convincing morphological characteristics of astrocytes
and oligodendrocytes. The tumour cells of both lineages may be
diffusely mixed or separated, but the latter form is rare. The
precise extent of the oligodendroglial versus astrocytic part is
often hard to define, also because these glial neoplasms generally
show areas in which the tumour cells are not easily recognized as
either astrocytic or oligodendroglial. Consequently, exact criteria
for distinguishing mixed oligoastrocytic tumours from pure
astrocytic or oligodendroglial neoplasms are not available, and
substantial inter-observer variability exists in the recognition of
these different types of diffuse gliomas.12 In daily clinical prac-
tice, diffuse gliomas lacking prototype oligodendroglial and
astrocytic phenotype of the tumour cells are often considered as
astrocytic neoplasms rather than diagnosed as glioma ‘not
otherwise specified’.
Within the glioblastoma category several phenotypical vari-
ants are recognized, the most frequent of these being giant cell
glioblastoma (with a predominance of multinucleated, giant
tumour cells), small cell glioblastoma (with a predominance of
small, relatively monomorphous tumour cells with little cyto-
plasm), and gliosarcoma (with extensive presence of a sarcoma-
toid phenotype). Recognition of these variants is important
because of the differential diagnosis with other tumours
requiring another treatment (e.g. giant cell glioblastoma versus
pleomorphic xanthoastrocytoma; small cell glioblastoma versus
anaplastic oligodendroglioma or PNET; gliosarcoma versus
meningeal or metastatic sarcoma). In this context the result of
immunohistochemistry for GFAP may be of little help. For
instance, both the small cell component of glioblastomas and
oligodendrogliomas are notorious for the lack of GFAP staining
of the tumour cells.Grading of diffuse gliomasAccording to the WHO-2007 classification diffuse gliomas are
graded as WHO grade II (low grade), WHO grade III (anaplastic)
or WHO grade IV (glioblastoma) whereas WHO grade I is
reserved for the more circumscribed gliomas.2 For grading of
diffuse gliomas the histological features nuclear atypia, mitotic
activity, necrosis, and florid microvascular proliferation (MVP)
are used (Figure 4). A diffuse astrocytic neoplasm without
marked mitotic activity, necrosis or florid MVP is diagnosed as
low-grade diffuse astrocytoma, irrespective of the degree of
nuclear atypia. When the tumour shows marked mitotic activityDIAGNOSTIC HISTOPATHOLOGY 17:11 489the diagnosis of anaplastic astrocytoma is rendered. The pres-
ence of necrosis and/or florid MVP leads to a diagnosis of glio-
blastoma. Often, necrosis in these tumours consists of irregular,
serpiginous foci surrounded by densely packed, somewhat radi-
ally oriented small tumour cells (‘pseudopalisading necrosis’).
In oligodendroglial and mixed oligoastrocytic tumours the
malignancy grade is assessed using the same set of histological
criteria but in a somewhat different way. In (pure) oligoden-
droglial tumours necrosis and florid MVP do not have the same
unfavourable connotation as in diffuse astrocytic neoplasms.
Oligodendrogliomas with MVP or necrosis are still considered as
WHO grade III lesions. In mixed oligoastrocytic tumours the
presence of MVP is compatible with WHO grade III, but the
presence of necrosis in this category leads to a diagnosis of
glioblastoma with oligodendroglial component (GBM-O). Exam-
ples of the histology of diffuse low-grade and high-grade
astrocytic, oligodendroglial, and oligoastrocytic tumours are
given in (Figure 5).
The scheme presented in Figure 4 may give the impression of
a robust and reproducible procedure. In daily clinical practice,
however, not only typing but also grading of gliomas can be
difficult. Firstly, tissue sampling can be incomplete and a whole
spectrum of other factors (pre-operative, surgical, pathological)
may negatively influence tissue quantity and quality, resulting in
a suboptimal diagnosis, e.g. underestimation of the true malig-
nancy in regionally heterogeneous tumours (Figure 6). Secondly,
the reproducibility of the WHO criteria for typing and grading of
diffuse gliomas is not optimal also due to the fact that it is
impossible to capture the biological variation in these tumours in
strict criteria. The scoring of nuclear atypia is problematic
because no scale for scoring is available. In addition, the degree
of cell density and nuclear atypia may not correlate with overall
malignancy grade: low-grade oligodendrogliomas are often
highly cellular while parts of glioblastomas may show moderate
cellularity. Significant nuclear atypia may be encountered in
otherwise low-grade gliomas while not be a prominent feature in
glioblastomas.
Evaluation of mitotic activity should be performed in the
context of sample size: a single mitosis in a large resection
specimen is not sufficient for the diagnosis of anaplastic glioma,
whereas the identification of a single mitosis in a small biopsy
fragment may well indicate high proliferative activity and thus 2011 Elsevier Ltd. All rights reserved.
Figure 5 Examples of microscopic features of diffuse gliomas and non-neoplastic glial cells: (a) GFAP positive reactive astrocytes; (b) oligodendrocytes in
normal white matter; (c) diffuse low-grade (fibrillary) astrocytoma; (d) gemistocytic astrocytoma; (e) low-grade oligodendroglioma (arrows indicate
calcifications); (f ) anaplastic oligodendroglioma; (g) GFAP staining of minigemistocytes and gliofibrillary cells in oligodendroglial tumour; (h) glioblas-
toma with oligo-component (arrow indicates pseudopalisading necrosis); (i) glioblastoma with florid/glomeruloid microvascular proliferation and
pseudopalisading necrosis; (j) small cell variant of glioblastoma with pseudopalisading necrosis; (k) giant cell glioblastoma; (l) gliosarcoma. All images
show haematoxylin-and-eosin staining and orig. magn. 200, except for a, g (GFAP staining, orig. magn. 400).
MINI-SYMPOSIUM: NEURO-ONCOLOGYa WHO grade III neoplasm. The Ki-67/MIB-1 labelling index
increases with malignancy grade (roughly in low-grade tumours
<5%, in anaplastic gliomas between 5% and 10%, and in glio-
blastomas over 10%). However, MIB-1 labelling index is not
routinely incorporated into a grading system because of
substantial overlap of this marker for the different malignancy
grades, tumour heterogeneity and differences in staining results
between different laboratories.Figure 6 Important determinants for quality and quantity of tissue used for m
system.
DIAGNOSTIC HISTOPATHOLOGY 17:11 490In glioblastomas prominent, often ‘glomeruloid’ MVP and/or
necrosis emerge. These features are generally spatially and
temporally distributed.9 Florid MVP is a term used for the presence
of multilayered microvessels with hypertrophy and hyperplasia of
endothelial cells and pericytes in the vessel walls. The minimum
requirements for recognition of this phenomenon are not clear.
Also the recognition of necrosis may be troublesome in biopsy
samples that are small or poorly preserved. As a consequenceicroscopic and molecular diagnostics of tumours of the central nervous
 2011 Elsevier Ltd. All rights reserved.
MINI-SYMPOSIUM: NEURO-ONCOLOGYsubstantial inter-observer variation exists in the classification of
diffuse gliomas even among experienced neuropathologists, which
may well have undesirable clinical consequences.12,13
Molecular analysisMolecular aberrations in diffuse gliomasFigure 7 Indication of diffuse glioma types and malignancy grades in
which particular molecular aberrations are relatively common.Like other cancers, diffuse gliomas result from (epi)genetic
alterations that lead to inactivation of tumour suppressor genes
or activation of proto-oncogenes and that accumulate with
tumour progression. Low-grade diffuse astrocytomas frequently
show mutation of the tumour suppressor gene TP53 (located at
17p13.1), loss of heterozygosity (LOH) on chromosome arm 17
p, and gains on the long arm of chromosome 7 (7q). In contrast,
combined and complete loss of the short arm of chromosome 1
(1p) and of the long arm of chromosome 19 (19q) is present in
the vast majority of typical oligodendroglial tumours. The
complete 1p/19q co-deletion results from a translocation
between chromosome 1 and 19. Some gliomas histopathologi-
cally diagnosed as oligoastrocytic tumour genetically resemble
either pure astrocytic or oligodendroglial tumours. Recently,
mutation of the isocitrate dehydrogenase 1 (IDH1) gene (less
commonly of the IDH2 gene) was identified as a common and
early event in the oncogenesis of low-grade and anaplastic
diffuse gliomas.8
Anaplastic diffuse gliomas often carry additional, progression-
associated genetic changes such as loss of the tumour suppressor
genes CDKN2A (coding for p14ARF and p16INK4A), CDKN2B on
9p21, deletions on chromosomes 6, 11p, 22q, amplification of
CDK4 or CDK6, inactivating alterations of RB1. The vast majority
of glioblastomas present de novo in elderly patients with a short
clinical history (‘primary glioblastomas’). In contrast, ‘secondary
glioblastomas’ develop by progression from pre-existing lower
grade gliomas. While primary glioblastomas frequently show
EGFR amplification and PTEN mutation and lack IDH1 mutation,
the secondary glioblastomas are characterized by frequent
mutations in the TP53 and IDH1 genes while lacking EGFR
amplification. Additionally, at the chromosomal level, primary
glioblastomas are distinct from secondary glioblastomas by the
frequent occurrence of trisomy of chromosome 7, monosomy of
chromosome 10, and gains of chromosome arms 12p, 19q and
20q. Despite these differences and the slightly better prognosis
for patients with secondary glioblastomas, most of the genetic
alterations in primary and secondary glioblastomas can be
assigned to a common set of functional pathways.8,14e16
Evidence is accumulating that certain molecular changes can
be used as biomarkers that provide additional diagnostic, prog-
nostic and/or predictive information that supplements or even
overrules the information provided by microscopic investigation.
Thereby, these markers can be used to improve tailored
management of glioma patients. The presently most promising
molecular markers in diffuse gliomas are combined deletion of
the chromosome arms 1 p and 19q, IDH1 and IDH2 mutations,
hypermethylation of the MGMT promoter, and EGFR amplifica-
tion/EGFRvIII expression (Figure 7).8,17 These aberrations are
discussed in somewhat more detail below. The role of molecular
diagnostics can be expected to rapidly increase. For instance,
effective implementation of targeted therapeutic approaches
using ‘small molecules’ will require information on the relevant
molecular components in individual tumours.DIAGNOSTIC HISTOPATHOLOGY 17:11 4911 p/19q lossLosses of 1p and 19q are detected in up to 80% of low grade oli-
godendrogliomas and approximately 60% of anaplastic oligoden-
drogliomas, whereas 30e50% of low grade oligoastrocytomas,
15e20% of anaplastic oligoastrocytomas, and less than 10% of
diffuse astrocytic gliomas, including the glioblastomas, carry this
aberration. There is a strong association between 1p/19q co-dele-
tion and classical oligodendroglial features on histology. Discus-
sion remains regarding the predictive (response to therapy) versus
prognostic (independent of therapy) nature of this marker. Recent
evidence suggests that 1p/19q loss characterizes a group of gliomas
that are more sensitive to genotoxic therapy (radiotherapy and
alkylating chemotherapy) in general and is associated with signif-
icantly longer survival. The prognostic relevance of 1p/19q loss
may be less pronounced in the presence of other, prognostically
unfavourable genetic alterations. Dependent on the exact set of
probes used, loss of heterozygosity (LOH) or (fluorescent) in situ
hybridization ((F)ISH) analysis (i.e. the most commonly used
techniques for 1p/19q testing in daily clinical practice) may not
allow for the distinction between tumours with partial, terminal or
interstitial 1p or 19q loss and those with complete, combined
1p/19q loss. As several studies now demonstrated that in this
context only complete co-deletion of 1p and 19q signifies a more
favourable prognosis, it is important to use a technique for
molecular diagnosis that allows for robust recognition of complete
loss of these chromosome arms. Testing for 1p/19q co-deletion is
nowadays often used to stratify patients into different clinical
trials.8,16IDH1/IDH2 mutationsOnly in 2008 mutations in the gene encoding the human cytosolic
NADPH-dependent isocitrate dehydrogenase (IDH1) were identi-
fied using large-scale sequencing analysis of 22 glioblastomas.18
The mutations were detected preferentially in glioblastomas of
young patients and in secondary glioblastomas. Soon after,
multiple studies corroborated these findings and additionally
revealed that somatic IDH1 (and less frequently IDH2) mutations
are present in the vast majority of diffuse, low-grade and
anaplastic gliomas and are strongly associated with better
outcome. The presence of IDH1 mutations in diffuse gliomas is
strongly correlated with TP53 mutation or 1p/19q deletion and
seems to represent a very early event affecting a common glial
precursor cell. The fact that the vastmajority of high-grade gliomas
in the paediatric age group lacks IDH1 mutation corroborates the
notion that these paediatric neoplasms are fundamentally different
from their adult counterparts. It is increasingly clear that the
heterozygous IDH1 and IDH2mutations in gliomas not just result 2011 Elsevier Ltd. All rights reserved.
MINI-SYMPOSIUM: NEURO-ONCOLOGYin a loss of function but also cause excessive production of the
‘oncometabolite’ 2-hydroxyglutarate (2HG). Testing formutations
in IDH1 or IDH2 can now effectively be performed using various
molecular methods. Additionally, specific monoclonal antibodies
were established that allow for immunohistochemical analysis of
the product of the most frequently occurring IDH1 mutation
(R132H; representing >90% of the IDH mutations in gliomas).
IDH1 and IDH2mutation analysis or immunohistochemistry using
the antibody against the IDH1 R132H mutated protein may be of
help in the differential diagnosis of diffuse glioma versus pilocytic
astrocytoma or ependymoma, for discrimination between primary
and secondary glioblastoma, and in the differential diagnosis of
diffusely infiltrating glioma versus reactive astrogliosis.8MGMTThe O6-methylguanineeDNA methyltransferase (MGMT) gene is
located at chromosome 10q26. In diffuse gliomas this gene is
frequently silenced by promoter hypermethylation. An association
has been reported between this epigenetic event and the response
of malignant gliomas to alkylating chemotherapy. The predictive
significance ofMGMT promoter status can be explained by the fact
that MGMT encodes a DNA repair protein that removes alkyl
groups from the O6 position of guanine, which are introduced by
alkylating chemotherapeutic agents (like temozolomide) that are
frequently used in glioma patients. In other studies, however,
a prognostic favourable effect ofMGMT promoter methylation was
found in patients receiving radiotherapy only, indicative of
a prognostic effect besides the putative predictive effect. Interest-
ingly, MGMT hypermethylation in diffuse gliomas is strongly
associated with prognostically favourable molecular features such
as 1p/19q co-deletion and IDH1 mutation. MGMT promoter
methylation may thus indeed reflect a global molecular constel-
lation that is associated with higher sensitivity to cytotoxic therapy
and more favourable outcome. Testing for MGMT promoter
methylation is usually performed by methylation-specific poly-
merase chain reaction (MSP or MS-PCR), methylation-specific
pyrosequencing or methylation-specific multiplex ligation-
dependent probe amplification (MS-MLPA). Alternative tests
such as simple immunohistochemical analysis of MGMT protein
expression or expression analyses based on Western blotting,
reverse transcription-PCR, or biochemical assays detecting enzy-
matic activity have proven to be difficult to interpret because of
the presence of contaminating non-neoplastic cells in the investi-
gated tissue specimens. It is important to realize that the MGMT
promoter methylation pattern is very heterogeneous from tumour
to tumour and that the relevant (combinations of) CpG sites in the
MGMT promoter that need to be methylated to silence transcrip-
tion are not yet defined.8,19EGFR amplification/EGFRvIIIThe epidermal growth factor receptor gene (EGFR) at chromo-
some 7p12 is the most frequently amplified and overexpressed
gene in primary glioblastomas, affecting approximately 40% of
these tumours. EGFR rearrangements are also frequently found.
The most common EGFR variant is variant III (EGFRvIII ), con-
sisting of an 801-bp in-frame deletion of exons 2e7 that results in
a constitutively activated truncated receptor protein lacking the
ligand binding domain. Identification of EGFR amplification and
rearrangements (like EGFRvIII ) is suggestive of high-gradeDIAGNOSTIC HISTOPATHOLOGY 17:11 492malignancy and therefore may provide diagnostic as well as
prognostic information. In fact, detection of EGFR amplification/
EGFRvIII in anaplastic or low-grade gliomas strongly suggests
that these tumours are more malignant than indicated by their
histopathology. Detection of EGFR aberrations also may be rele-
vant from a therapeutic point of view. Up till now, the clinical
benefit of the use of EGFR inhibitors in glioblastomas has been
rather disappointing. However, the EGFRvIIImutant may serve as
an attractive target for immunotherapy, and recent studies re-
ported that the anti-EGFRvIII peptide vaccine CDX-110 increased
progression free and overall survival in EGFRvIII-positive glio-
blastoma patients. Existing patents currently prohibit the use of
an antibody specifically recognizing EGFRvIII for immunohisto-
chemistry in the clinic. As an alternative, EGFRvIII analysis can
be performed by reverse transcription-PCR analysis using
primers located in exon 1 and 9 or by MLPA analysis.8,16Multidisciplinary approachRadiological presentationClinical information (esp. patient age, duration of symptoms,
previous treatment) and radiological findings (including location
and growth pattern of the tumour, contrast-enhancement) provide
important clues for narrowing down the differential diagnosis in
patients with a tumour of the CNS.4 Magnetic resonance imaging
(MRI) is now the gold standard for radiological assessment of
these tumours and can in fact be used by pathologists as a surro-
gate for the macroscopy of these neoplasms.
Low-grade diffuse gliomas show hyperintensity on T2 weighted
MRI scans but generally do not enhance in T1 weighted images
when using the contrast-agent Gadolinium-DTPA. The absence of
contrast-enhancement in these tumours can be explained by
incorporation (‘co€option’) of preexistent microvessels with only
limited changes to the bloodebrain barrier (BBB) and lack of neo-
vascularization. Contrast-enhancement onMRI scans of high-grade
gliomas indicates disruption of the BBB of preexistent or newly
formed microvessels. Many glioblastomas present radiologically
with a non-enhancing, necrotic core surrounded by a contrast-
enhancing ring of viable, highly cellular and angiogenic tumour
tissue (ring-enhancement). However, the invasive front of these
tumours is difficult to visualize by radiology, also because the
periphery of high-grade malignant gliomas often lacks contrast-
enhancement. Correlation of histological sections of glioblastomas
with radiology revealed that tumour cells of diffuse gliomas are
often present several centimetres outside the enhancing area and
even outside the hyperintense areas on T2 weighted MR images.9
Radiological informationmay be very helpful in cases where the
differential diagnosis of e.g. diffuse versus circumscribed glioma is
difficult for the pathologist. Occasionally, in patients with multiple
contrast-enhancing lesions in the brain and a clinical differential
diagnosis of metastatic or inflammatory/infectious disease, histo-
pathological analysis reveals a diffuse glioma. This latter presen-
tation can often be explained by multifocal dedifferentiation in
a widespread diffuse glioma of lower malignancy grade.Multidisciplinary approach: mandatory!Even when clinical and radiological information is not available,
in some cases the pathologist may be able to make an unequiv-
ocal and correct diagnosis on a brain tumour biopsy alone (e.g. 2011 Elsevier Ltd. All rights reserved.
Figure 8 Case illustrating the importance of a multidisciplinary approach in the pathological diagnosis of brain tumours. A 58-year old woman showed
a small, ring-enhancing lesion deep in the left cerebral hemisphere on MRI scans after Gadolinium (a); with a neuro-navigation guided biopsy procedure
small tissue fragments were obtained for pathological analysis (fragments in container with physiologic salt solution (b), top of container (c) and paraffin
block (d)); the vast majority of the haematoxylin-and-eosin stained slides of these fragments (e, f ) revealed a low-grade diffuse astrocytoma; only in the
periphery of one fragment (rectangle in f ) one spot was found with florid microvascular proliferation (f ); combining the pathology (diffuse astrocytic
tumour, largely low grade, but with focal florid microvascular proliferation consistent with glioblastoma) with the radiology (ring-enhancing lesion highly
suggestive of a necrotic core in the tumour) led to a final ‘multidisciplinary’ diagnosis of glioblastoma; the biopsy material was considered as
a peripheral, not fully representative part of the lesion.
MINI-SYMPOSIUM: NEURO-ONCOLOGYglioblastoma). However, diffuse gliomas often show marked
phenotypical heterogeneity with spatial differences in cellular
phenotype and malignancy grade. When only small biopsies are
available the malignancy grade of diffuse gliomas may therefore
be underestimated (Figure 8). Also, it is impossible to make
a diagnosis of gliomatosis cerebri (i.e. the most extreme example
of diffuse infiltrative glioma) on histopathological analysis of
a biopsy alone, as the required involvement of at least three
cerebral lobes (and usually bilateral growth) can only be
appreciated by evaluation of radiological images or in post-
mortem material. Both radiological and pathological assess-
ment of response to different treatment strategies for diffuse
gliomas can be challenging. For example, distinguishing pureFigure 9 Case illustrating problematic differential diagnosis between therapy e
low-grade astrocytoma (a) in the right frontal lobe for which he received chem
after his initial biopsy MRI scans with Gadolinium revealed a rapidly growing
radionecrosis (b); histopathologically, in a biopsy of this lesion fibrinoid necros
to paucicellular tumour tissue lacking (other) features of high-grade malignan
lesion (d), corroborating the notion that this patient suffered from radionecro
DIAGNOSTIC HISTOPATHOLOGY 17:11 493radiation necrosis from radiation necrosis with recurrent glioma
in biopsy material is often virtually impossible (Figure 9).20
In this context we advocate that in daily clinical practice the
pathologist starts formulating a diagnosis based on the
morphological features in brain tumour specimens and subse-
quently puts the morphological diagnosis in perspective of the
relevant clinical and radiological findings. In our view, the
pathologist should actively participate in multidisciplinary
neuro-oncology meetings in order to be able to ‘fine-tune’ the
pathological diagnosis and to check if additional molecular
testing is warranted. Such a multidisciplinary approach in the
diagnosis of diffuse gliomas is a key for optimal management of
patients with these tumours.ffect and recurrent glioma. A 28-year old male was diagnosed with diffuse,
otherapy (1) and irradiation (2) in the course of multiple years; 5 years
lesion suspect for glioblastoma but with a differential diagnosis of
is was present consistent with radionecrosis and with a gradual transition
cy (c); MRI scans 5 months later revealed spontaneous regression of the
sis rather than from malignant progression of the diffuse glioma.
 2011 Elsevier Ltd. All rights reserved.
Practice points
C The group of gliomas encompasses many different histological
types and malignancy grades.
C Most gliomas, the so-called ‘diffuse gliomas’, are characterized
by diffuse infiltrative growth in the preexistent parenchyma of
the CNS.
C Diffuse gliomas are subtyped as astrocytic, oligodendroglial,
or oligoastrocytic based on the resemblance of tumour cells
with non-neoplastic astrocytes and/or oligodendrocytes.
C Diffuse gliomas are graded as low grade (WHO grade II),
anaplastic (WHO grade III), or glioblastoma (WHO grade IV)
based the presence of nuclear atypia, mitotic activity, florid
microvascular proliferation, and necrosis.
C Accurate distinction between the different diffuse glioma types
and malignancy grades has significant prognostic and thera-
peutic implications.
C Histopathological typing and grading of diffuse gliomas can be
challenging because of sampling effect and lack of unequivocal
criteria.
C Molecular diagnostics is a promising tool for more robust
classification of diffuse gliomas.
C The presently most relevant molecular markers in diffuse
gliomas are complete 1 p/19q co-deletion, IDH1/IDH2 muta-
tion, MGMT promoter methylation, and EGFR amplification/
EGFRvIII expression.
C The pathological diagnosis of diffuse gliomas should be
evaluated in the context of clinical and radiological findings.
MINI-SYMPOSIUM: NEURO-ONCOLOGYConcluding remarks and future perspectives
The unique diffuse infiltrative growth of gliomas in the brain
parenchyma has important diagnostic, prognostic, and thera-
peutic implications. In a clinical setting combination of clinical,
radiological, and pathological information is warranted to avoid
diagnostic inaccuracy, particularly in cases where only small
biopsy specimens are available for pathological diagnosis. So far,
histopathology is the gold standard for typing and grading of
gliomas. However, histological classification of gliomas is asso-
ciated with significant inter-observer variability.
Molecular diagnostics is a promising tool for more robust
classification of diffuse gliomas. The challenge is then to
combine the classic morphological approach with molecular
diagnostics in order to provide the best possible information for
the individual patient. The result of this combined approach may
well be that parts of the morphological system for typing and
grading of diffuse gliomas will become less relevant or even
overruled by certain molecular findings. Meanwhile, parameters
like tissue quality and quantity are of utmost importance also for
molecular diagnostics and the pathologist as ‘tissue professional’
is instrumental in the assessment and selection of the material
that is used for subsequent molecular testing.
Our knowledge on the genes and pathways involved in the
oncogenesis of diffuse gliomas can be expected to substantially
expand further in the near future. Hopefully, this will reveal
novel clinically useful markers and pave the way to the devel-
opment of more effective drugs, thereby providing better
opportunities for individualized therapy of patients with these so
far incurable cancers. A
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